RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Five Prime Therapeutics Stock

Five Prime Therapeutics P/E 2024

Five Prime Therapeutics P/E

-15.03

Ticker

FPRX

ISIN

US33830X1046

WKN

A1W5T9

As of Sep 29, 2024, Five Prime Therapeutics's P/E ratio was -15.03, a 0% change from the 0 P/E ratio recorded in the previous year.

The Five Prime Therapeutics P/E history

Five Prime Therapeutics Aktienanalyse

What does Five Prime Therapeutics do?

Five Prime Therapeutics Inc. is a biotech company based in South San Francisco, California. It specializes in the discovery and development of innovative therapeutics for serious diseases. The company was founded in 2001 by leading biotechnology researchers and has undergone several mergers and acquisitions. It is currently listed on the Nasdaq stock exchange under the ticker symbol "FPRX". Five Prime Therapeutics' business model is based on the discovery and development of therapeutics for diseases that have been inadequately treated. The company focuses on precision medicine approaches tailored to the individual needs of patients. Its main areas of focus include cancer therapies, inflammatory diseases, and rare genetic diseases. To achieve these goals, the company utilizes a wide range of therapeutic platforms, including antibodies, biologics, and protein therapies. These platforms are based on a deeper understanding of disease processes and mechanisms, as well as a precise understanding of biological and molecular connections in the human body. Five Prime Therapeutics also utilizes artificial intelligence and machine learning in the development of new therapeutics. The company has four main divisions: oncology, immunology, women's health, and genomics/proteomics. Each division focuses on specific indications and development programs. Some key developments and products in each division include: - Oncology: Five Prime Therapeutics has a broad pipeline of precision oncology therapeutics. One of the most important development programs is "FPA150," an antibody targeting B7-H4, a protein expressed by cancer cells. FPA150 is being tested in clinical studies for the treatment of solid tumors and cervical cancer. - Immunology: The company has also developed a pipeline of immunotherapeutics and biologics targeting the treatment of inflammatory diseases such as rheumatoid arthritis and Crohn's disease. One of the key development programs in this area is "FP-028," which targets the TGF-beta signaling pathway. - Women's Health: Five Prime Therapeutics also has a division focused on women's health. An important development program in this area is "FP-1039/GSK3052230," a biologic that could potentially be used for the treatment of ovarian cancer. - Genomics/Proteomics: As the fourth main division, the company is working on biomarker-based therapeutics targeting specific genetic mutations and signaling pathways. An important component of this work is the identification of new target molecules through genomics and proteomics technologies. Overall, Five Prime Therapeutics has achieved an impressive track record in the discovery and development of innovative therapeutics in recent years. Several of its main programs have successfully entered clinical studies and are showing promising results. Additionally, the company has established a successful partnership with GlaxoSmithKline to jointly develop new therapeutics for the treatment of cancer and inflammatory diseases. In summary, Five Prime Therapeutics is an emerging biotech company specialized in the discovery and development of innovative therapeutics for serious diseases. Through its precision medicine business model and wide range of therapeutic platforms, the company has made successful progress in the development of promising therapeutics. Five Prime Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Five Prime Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Five Prime Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Five Prime Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Five Prime Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Five Prime Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Five Prime Therapeutics stock

What is the price-to-earnings ratio of Five Prime Therapeutics?

The price-earnings ratio of Five Prime Therapeutics is currently -15.03.

How has the price-earnings ratio of Five Prime Therapeutics changed compared to last year?

The price-to-earnings ratio of Five Prime Therapeutics has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Five Prime Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Five Prime Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Five Prime Therapeutics affect the company?

An increase in the price-earnings ratio of Five Prime Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Five Prime Therapeutics affect the company?

A decrease in the price-earnings ratio of Five Prime Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Five Prime Therapeutics?

Some factors that influence the price-earnings ratio of Five Prime Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Five Prime Therapeutics pay?

Over the past 12 months, Five Prime Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Five Prime Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Five Prime Therapeutics?

The current dividend yield of Five Prime Therapeutics is .

When does Five Prime Therapeutics pay dividends?

Five Prime Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Five Prime Therapeutics?

Five Prime Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Five Prime Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Five Prime Therapeutics located?

Five Prime Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Five Prime Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Five Prime Therapeutics from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Five Prime Therapeutics pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Five Prime Therapeutics in the year 2023?

In the year 2023, Five Prime Therapeutics distributed 0 USD as dividends.

In which currency does Five Prime Therapeutics pay out the dividend?

The dividends of Five Prime Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Five Prime Therapeutics

Our stock analysis for Five Prime Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Five Prime Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.